Company intelligence / Profile preview

Fountain Biopharma Inc.

New Taipei City, Taipei, Taiwanfountainmab.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Lead programs are in early clinical stages. FB825 is in Phase II trials for allergic diseases; other assets are in Phase I or preclinical stages. Some programs have been outlicensed or co-developed with academic partners such as Academia Sinica.

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Monoclonal antibodiesDNA aptamers
Industry: Biotech

Partnerships

Academia Sinica (co-development of anti-IgE mAb)CHO Pharma collaboration on glycosylated mAbspossible licensing/outlicensing deals with international pharma companies for lead assets like FB825.

Beyond the preview

Go deeper on Fountain Biopharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fountain Biopharma Inc..